This session explores viewpoints around the potential for psychedelic-assisted therapies to treat adolescents.
Today, adolescents are using prescribed substances such as ketamine to address treatment resistant depression. Soon, the FDA may require sponsors of approved psychedelic medications to conduct additional studies with adolescents.
Historically, children have ingested age-appropriate doses of plant medicines in ceremonial contexts within indigenous communities.
While these treatments are promising, they must carefully assessed for risks and thoughtfully designed for use among a younger audience.
